ASCORBIC ACID ( DrugBank: Ascorbic acid )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
10シャルコー・マリー・トゥース病7
97潰瘍性大腸炎2
206脆弱X症候群2
298遺伝性膵炎1

10. シャルコー・マリー・トゥース病


臨床試験数 : 41 薬物数 : 46 - (DrugBank : 9) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 15
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs031190109
25/10/201903/10/2019Ascorbic acid treatment for childhood Charcot-Marie-Tooth disease 1AAscorbic acid treatment for childhood Charcot-Marie-Tooth disease 1A - Ascorbic acid for CMT1A Charcot-Marie-Tooth disease type 1A
CMT1A;G600
ascorbic acid dayly intakeSHIOHAMA TADASHINULLRecruitingNot applicable< 18age oldBoth12Phase 2Japan
2JPRN-UMIN000036332
2019/06/1528/03/2019Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1AAscorbic acid treatment for Charcot-Marie-Tooth disease type 1A - Ascorbic acid treatment for CMT1A Charcot-Marie-Tooth diease type 1AAscorbic acid treatment: 20mg/kg/day, daylyChiba UniversityNULLPending1years-oldNot applicableMale and Female10Phase 1Japan
3NCT00484510
(ClinicalTrials.gov)
April 20078/6/2007High Dose Ascorbic Acid Treatment of CMT1AA Randomized, Placebo-controlled, Double Masked 120 Subject Futility Design Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A.Charcot-Marie-Tooth Disease, Type IaDrug: Ascorbic acid (Vitamin C);Drug: placeboWayne State UniversityMuscular Dystrophy Association;Charcot-Marie-Tooth AssociationCompleted13 Years70 YearsBoth110Phase 2/Phase 3United States
4NCT00271635
(ClinicalTrials.gov)
January 20063/1/2006Ascorbic Acid Treatment in CMT1A Trial (AATIC)Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1ACharcot-Marie-Tooth Disease;Hereditary Motor and Sensory NeuropathiesDrug: Placebo;Drug: ascorbic acidAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NULLCompleted12 Years25 YearsBoth13Phase 2Netherlands
5EUCTR2006-000032-27-IT
(EUCTR)
19/10/200514/03/2006MULTICENTRE RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACID TREATMENT IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A CMT-TRIAAL CMT-TRial Italian with Ascorbic Acid Long term - CMT-TRIAALMULTICENTRE RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACID TREATMENT IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A CMT-TRIAAL CMT-TRial Italian with Ascorbic Acid Long term - CMT-TRIAAL Charcot-Marie-Tooth disease type 1A CMT1A
MedDRA version: 6.1;Level: HLGT;Classification code 10034606
Trade Name: CEBION 500MG 20CPR MAST.ARAN
INN or Proposed INN: ACIDO ASCORBICO DC.IT
INN or Proposed INN: SODIO ASCORBATO DC.IT
ISTITUTO NEUROLOGICO CARLO BESTANULLNot RecruitingFemale: yes
Male: yes
202Italy
6JPRN-UMIN000001535
2005/04/0101/01/2009A multicenter, randomized open trial of ascorbic acid treatment in Charcot-Marie-Tooth disease type 1AA multicenter, randomized open trial of ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A - CMT-AA Charcot-Marie-Tooth disease 1AAscorbic acid (AA) treatment group
(12 weeks oral AA (20mg/kg/day)
no AA treatment group
New treatment strategies for intractable neuropathies based on its pathomechanism.The Research Grant 19A-5 for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare.NULLComplete: follow-up complete15years-old75years-oldMale and Female60Phase 1,2Japan
7EUCTR2004-004501-24-IT
(EUCTR)
22/12/200413/02/2007Multicentre, randomised, double blind, placebo controlled trial of ascorbic acid treatment in Charcot-Marie-Tooth Disease Type 1A CMT1A .Multicentre, randomised, double blind, placebo controlled trial of ascorbic acid treatment in Charcot-Marie-Tooth Disease Type 1A CMT1A . Charcot-Marie-Tooth Disease Type 1A CMT1A .
MedDRA version: 6.1;Level: HLT;Classification code 10022031
Trade Name: CEBION 500*20CPR MAST 500MG
Product Name: ACIDO ASCORBICO
INN or Proposed INN: Ascorbic acid vit C
ISTITUTO NEUROLOGICO CARLO BESTANULLNot RecruitingFemale: yes
Male: yes
200Italy

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03581149
(ClinicalTrials.gov)
March 26, 201827/3/2018Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis PatientsTolerability and Efficacy of Low-Volume Sodium Picosulfate/Magnesium Citrate Versus 2L Polyethylene Glycol/Ascorbic Acid in Patients With Ulcerative Colitis Undergoing Colonoscopy: A Randomized Controlled TrialUlcerative ColitisDrug: Sodium Picosulfate/Magnesium Citrate Laxative;Drug: 2L polyethylene glycol/ascorbic acidAmerican University of Beirut Medical CenterNULLRecruiting18 Years65 YearsAll68Phase 4Lebanon
2NCT01929668
(ClinicalTrials.gov)
August 201323/8/2013Comparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acid in Inactive UC PatientsComparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acid in Patients With Inactive Ulcerative Colitis; Randomized, Single Blind, Multicenter StudyUlcerative ColitisDrug: polyethylene glycol;Drug: Ascorbic AcidKyungpook National UniversityNULLCompleted18 Years80 YearsBoth114N/AKorea, Republic of

206. 脆弱X症候群


臨床試験数 : 108 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-005460-42-ES
(EUCTR)
07/07/201620/04/2016Clinical trial to evaluate ascorbic acid (vitamin C) and tocopherol (vitamin E) in combination versus placebo for the treatment of cognitive and behavioral disorders in children with fragile x syndromePhase III clinical trial, double-blind, cross-way, to evaluate the safety and efficacy ascorbic acid (vitamin C) and tocopherol (vitamin E) combination versus placebo for the treatment of cognitive and behavioral disorders in children with fragile x syndrome Fragile x syndrome
MedDRA version: 19.0;Level: PT;Classification code 10017324;Term: Fragile X syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Vitamin C
INN or Proposed INN: Vitamin C
Other descriptive name: ACIDUM ASCORBICUM D6
Product Name: Vitamin E
INN or Proposed INN: Vitamin E
Other descriptive name: TOCOPHERYL ACETATE
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludNULLNot RecruitingFemale: no
Male: yes
Phase 3Spain
2NCT01329770
(ClinicalTrials.gov)
December 201029/3/2011Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X SyndromePhase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X SyndromeFragile X SyndromeDietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E);Dietary Supplement: PlaceboYolanda de Diego OteroNULLCompleted6 Years18 YearsMale30Phase 2Spain

298. 遺伝性膵炎


臨床試験数 : 95 薬物数 : 148 - (DrugBank : 51) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-000087-83-GB
(EUCTR)
19/12/200804/12/2007EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis. - EUROPAC2EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis. - EUROPAC2 Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis
MedDRA version: 13.1;Level: HLT;Classification code 10033646;Term: Acute and chronic pancreatitis;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 13.1;Level: PT;Classification code 10056976;Term: Hereditary pancreatitis;System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: Magnesiocard 2.5mmol
Other descriptive name: MAGNESIUM ASPARTATE HYDROCHLORIDE
Product Name: ANTOX (vers) 1.2
Product Code: ANTOX
Other descriptive name: TOCOPHEROL
INN or Proposed INN: ASCORBIC ACID
Other descriptive name: SELENIUM
INN or Proposed INN: METHIONINE
University of LiverpoolThe Royal Liverpool and Broadgreen University Hospitals NHS TrustAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
240Phase 3United Kingdom